REGN and SNY get positive CHMP opinion on the label expansion of Dupixent in the EU for eosinophilic esophagitis in children down to 1 year of age.

Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant

Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed multiple myeloma, where it has previously been used only after standard tr...

Sanofi (NASDAQ:SNY ) ECTRIMS 2024 Investor Science Call September 20, 2024 10:00 AM ET Company Participants Thomas Kudsk - IR Jiwon Oh - MD, PhD, St. Michael's Hospital, University of Toronto, Toro...

Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later ...

REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.

Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers Paris, France, and Houston, Texas, September 12, 2024. As part of its effort ...

While reported use of Sanofi/Regeneron's Dupixent has declined with the adoption of LEO's Adbry, Pfizer's Cibinqo, and AbbVie's Rinvoq, the overall population receiving advanced treatments is on th...

The pharmaceutical-sector mainstay published news about its investigational multiple sclerosis drug. It did well in one trial but was less impressive in two others.

Sanofi's most advanced multiple sclerosis (MS) drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, dimming the prospects for a widely-pursued c...

Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis In the HERCU...

Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi Led by long-standing investor EcoR1 Capital with participation from addit...

Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant

Sanofi's second-quarter profit rose 3.2% on strong demand for its blockbuster asthma drug Dupixent and better-than-expected sales of new launches, with the company now expecting a stable full-year ...

NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A ALTUVIIIO provides high-sustained factor levels ...